In this article, we will discuss the 10 Tiny Stocks That Are On Fire Right Now.
On April 16, Fundstrat’s Tom Lee joined ‘Closing Bell’ to argue that the stock market is currently in a stronger position than it was earlier in the year when it reached all-time highs. He identified three primary reasons for this outlook: the US market’s ability to handle oil surges that are damaging other nations, rising earnings that suggest the war is stimulating the economy, and historical data indicating that oil spikes have a smaller impact on core inflation than previously feared. Based on these factors, Lee maintains a base case of 7,300 for the market this year within his three-phase market framework before expecting a larger drawdown.
Lee also confirmed that technology is expected to deliver the best earnings growth, while current valuations have become more attractive due to recent price declines. He characterized these tech companies as having true moats and a track record of growing earnings faster than the S&P 500. He views these firms as primary winners in the AI sector and suggests that buying them at a market multiple today will, in five years, be seen as a surprisingly cheap entry point.
Our Methodology
We used screeners to identify stocks that are trading between $300 million and $2 billion, and have exhibited strong year-to-date share price performance (at least 100%), and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on April 27.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Tiny Stocks That Are On Fire Right Now
10. Anterix Inc. (NASDAQ:ATEX)
Year-to-Date Performance: 113.47%
Anterix Inc. (NASDAQ:ATEX) is one of the tiny stocks that are on fire right now. On April 6, Anterix and NorthWestern Energy announced a milestone agreement for the first planned deployment of a 10 MHz broadband configuration in the 900 MHz band. This development follows the FCC’s unanimous February approval to expand Anterix’s spectrum allocation, nearly doubling the capacity available for utility providers.
NorthWestern Energy becomes the tenth utility to secure Anterix’s spectrum, highlighting a significant industry shift toward private, utility-controlled networks as a primary infrastructure for the energy transition. The expanded 10 MHz capacity is designed to provide a secure and reliable platform for modernizing critical energy infrastructure across vast and rugged terrains.
By using this broadband spectrum, NorthWestern Energy aims to achieve real-time control of remote distribution equipment and enhance situational awareness, particularly in high-risk wildfire areas. The network will also support redundant connectivity for field devices and more efficient service restoration during outages, ensuring safer and more reliable energy delivery for served communities. To support these deployments, Anterix Inc. is offering an integrated suite of services, including its TowerX nationwide tower access and CatalyX turnkey connectivity management.
Anterix Inc. commercializes spectrum assets to enable the targeted utility and critical infrastructure customers to deploy private broadband networks and solutions.
9. Spire Global Inc. (NYSE:SPIR)
Year-to-Date Performance: 115.60%
Spire Global Inc. (NYSE:SPIR) is one of the tiny stocks that are on fire right now. On April 9, Spire Global entered into a securities purchase agreement for a private placement expected to generate ~$70 million in gross proceeds. The company is selling 5 million shares of its Class A common stock for $14 per share, with the transaction slated to close around April 10.
Craig-Hallum Capital Group LLC served as the sole placement agent for the offering, which was conducted as a private transaction not involving a public offering. The satellite data and analytics provider intends to use the net proceeds to support working capital and general corporate purposes. A primary focus of the funding is to accelerate growth within high-demand sectors, such as space reconnaissance and government procurement of commercial weather data in both domestic and international markets.
Additionally, the company plans to invest in enhancing its sales and marketing infrastructure while advancing its technical capabilities in radio frequency geolocation and weather data solutions. A significant portion of the capital will also be directed toward cybersecurity, specifically the hardening of Spire Global Inc.’s (NYSE:SPIR) infrastructure to better support sovereign data requirements and proprietary constellation opportunities.
Spire Global Inc. provides space-based data, analytics, and satellite services. Its datasets help organizations monitor conditions on Earth and support decision-making across industries.
8. Blue Moon Metals Inc. (NASDAQ:BMM)
Year-to-Date Performance: 129.68%
Blue Moon Metals Inc. (NASDAQ:BMM) is one of the tiny stocks that are on fire right now. On April 16, Blue Moon Metals announced the completion of a feasibility study for its Nussir project in northern Norway, confirming its potential as a robust, long-life mining asset. The study outlines a 13-year mine life with an average annual free cash flow of $77 million based on consensus pricing, which jumps to $125 million at recent spot prices.
With a total proven and probable reserve estimate of 24.98 million tonnes at 0.99% copper equivalent, the project remains open for future resource growth. The company has already advanced basic engineering and secured long-lead equipment, targeting hot commissioning of the process plant by Q3 2027.
The project’s economic highlights include an after-tax net present value of $235 million and an internal rate of return of 19% at consensus pricing. The life-of-mine average annual production is estimated at 19,000 tonnes of copper equivalent, supported by significant gold and silver by-products. Initial capital expenditures are projected at $184 million, with total cash costs net of by-products standing at a competitive $0.95 per pound of copper. Blue Moon Metals Inc. has already invested ~$46.7 million into the site, and the ongoing exploration decline is expected to reach the target mineralized material by mid-2026.
Blue Moon Metals Inc. is a Toronto-based mineral exploration company focused on zinc, gold, silver, and copper deposits in Norway and the US. The firm is currently advancing its flagship, 100%-owned Nussir project in northern Norway.
7. Climb Bio Inc (NASDAQ:CLYM)
Year-to-Date Performance: 138.12%
Climb Bio Inc (NASDAQ:CLYM) is one of the tiny stocks that are on fire right now. On April 7, Climb Bio received FDA Fast Track Designation for budoprutug, its investigational anti-CD19 monoclonal antibody, for the treatment of primary membranous nephropathy/pMN. This designation is intended to expedite the development and review of drugs that treat serious conditions and fill unmet medical needs. Currently, there are no FDA-approved therapies for pMN, a rare immune-mediated kidney disease affecting ~75,000 people in the US.
The FDA’s decision was supported by promising results from a Phase 1b study, where budoprutug achieved 100% peripheral B-cell depletion and clinical remission in all participating patients by week 48. The treatment also showed a favorable safety profile and durable reductions in proteinuria, suggesting its potential as a disease-modifying therapy. The Fast Track status will allow for more frequent interactions with the FDA and eligibility for priority review if supported by clinical data.
Budoprutug is currently being evaluated in PrisMN, a Phase 2 global open-label clinical trial. This study is assessing the drug’s efficacy in patients who have persistent proteinuria despite standard treatments, to identify the optimal dose for Phase 3 development. Climb Bio Inc expects to release initial data from the PrisMN study in H2 2026.
Climb Bio Inc is a clinical-stage biotechnology company. It is focused on developing therapies for immune-mediated diseases, with a pipeline centered on monoclonal antibodies targeting B-cell-driven conditions.
6. Compass Diversified Holdings (NYSE:CODI)
Year-to-Date Performance: 141.40%
Compass Diversified Holdings (NYSE:CODI) is one of the tiny stocks that are on fire right now. On March 30, Compass Diversified entered into a definitive agreement to sell the food service business of its subsidiary, Sterno, to Archer Foodservice Partners for $292.5 million. Archer, a portfolio company of Wynnchurch Capital, will acquire the division, which generated ~$30.3 million in adjusted EBITDA in 2025. Following the divestiture, Compass Diversified will retain Sterno’s home fragrance business, which will continue to operate under the Rimports name.
The primary objective of the sale is to accelerate the company’s deleveraging strategy. Compass Diversified intends to use the net proceeds to repay outstanding debt, which is expected to bring its senior secured net leverage ratio below 1.0x. By reducing this ratio before June 30, the company also expects to avoid fees associated with excess leverage, further strengthening its balance sheet and narrowing the gap between its market price and intrinsic value.
The transaction marks the end of a decade-long partnership between Compass Diversified and Sterno’s food service unit, a brand with a 125-year history in portable heat. Sterno CEO Geoffrey J. Feil will continue to partner with Compass Diversified Holdings but will shift his focus entirely to leading Rimports in the home fragrance and décor market. The deal is subject to regulatory approvals and is anticipated to close in May.
Compass Diversified Holdings is a holding company that acquires and manages controlling stakes in middle-market businesses across branded consumer and industrial sectors. Its portfolio includes subsidiaries involved in manufacturing, consumer products, and industrial services.
5. Silvaco Group Inc. (NASDAQ:SVCO)
Year-to-Date Performance: 157.41%
Silvaco Group Inc. (NASDAQ:SVCO) is one of the tiny stocks that are on fire right now. On April 20, Silvaco Group entered into a strategic partnership with Taiwan’s Industrial Technology Research Institute/ITRI to support the development of next-gen microcontroller units/MCUs. Under this agreement, ITRI will deploy Silvaco’s SmartSpice circuit simulation platform within its Nankang IC Design Incubation Center.
This integration is designed to provide startups with the high-precision verification and simulation tools necessary to accelerate development cycles for analog, mixed-signal, and RF circuit designs. The collaboration focuses on fostering semiconductor innovation by lowering the barrier to entry for emerging companies. By providing access to industry-standard EDA/Electronic Design Automation tools, Silvaco, and ITRI aim to streamline the transition from initial design to market-ready MCU solutions.
In addition to the software deployment, both organizations are exploring further opportunities to expand their support for the semiconductor ecosystem. This partnership aligns with Silvaco Group Inc.’s (NASDAQ:SVCO) broader strategy of providing AI-enabled TCAD and EDA solutions across high-growth markets such as automotive, IoT, and 5G/6G mobile systems.
Silvaco Group Inc. provides AI-enabled TCAD, EDA, and SIP solutions for global semiconductor design. Its software enables digital twin modeling and process optimization across diverse markets, including automotive, 5G/6G, and HPC.
4. Sutro Biopharma Inc. (NASDAQ:STRO)
Year-to-Date Performance: 183.15%
Sutro Biopharma Inc. (NASDAQ:STRO) is one of the tiny stocks that are on fire right now. On March 23, Sutro Biopharma reported its full-year 2025 financial results, highlighting a strengthened balance sheet and significant clinical milestones for its antibody-drug conjugate/ADC platform. The company ended 2025 with $141.4 million in cash and marketable securities, which, when combined with a recent $110 million capital raise, extends its cash runway into at least Q2 2028. This financial stability supports a sharpened focus on advancing both wholly owned and partnered oncology programs.
A major focus for 2026 is the progress of Sutro’s internal pipeline. The company completed dosing for the third cohort in its Phase 1 trial of STRO-004, a potential best-in-class Tissue Factor/TF ADC, with initial clinical data expected in mid-2026. Additionally, Sutro Biopharma Inc. is accelerating the development of STRO-227, its first wholly owned dual-payload program targeting PTK7, with an IND submission now targeted for 2026. The company also expects its ITGB6-targeting ADC, STRO-006, to enter clinical development this year.
Sutro’s collaboration with Astellas Pharma has also reached a key inflection point, with their first partnered dual-payload immunostimulatory ADC entering the clinic. Patient dosing is currently in Q2 2026. A second partnered program also advanced into IND-enabling toxicology studies late last year, further validating Sutro’s site-specific ADC platform through strategic partnerships.
Sutro Biopharma Inc. is a clinical-stage biotechnology company using a proprietary cell-free platform to develop next-gen antibody-drug conjugates/ADCs for cancer. By optimizing antibodies, linkers, and single or dual-payloads, the company aims to improve drug exposure and overcome treatment resistance in oncology markets with significant unmet needs.
3. Syntec Optics Holdings Inc. (NASDAQ:OPTX)
Year-to-Date Performance: 228.15%
Syntec Optics Holdings Inc. (NASDAQ:OPTX) is one of the tiny stocks that are on fire right now. On April 21, Syntec Optics secured a ~$2 million expansion order for integrated micro cameras designed for next-gen, AI-enabled AR systems for the US military. This contract follows the company’s successful execution of ballistic optics projects and marks a move into the sensing layer of defense technology.
The initial deployment serves as a foundation for projected recurring annual orders through 2030, as the US Department of Defense prioritizes equipping soldiers with advanced sensor fusion and computer vision capabilities. The micro cameras are mission-critical components that enable superhuman situational awareness by feeding raw optical data into AI software to create real-time, 3D battlefield maps.
To prevent motion sickness and ensure a stable digital overlay, these optics must meet nanoscale precision tolerances. Syntec’s purpose-built sensors are designed to maintain high fidelity under extreme thermal stress, small form factors, and low-light conditions, reducing latency to near zero. A key driver for this award is Syntec Optics Holdings Inc.’s (NASDAQ:OPTX) vertically integrated, US-based manufacturing footprint. The recent National Defense Authorization Act mandates require critical optical technologies to be manufactured domestically to ensure a secure, sovereign supply chain.
Syntec Optics Holdings Inc. is an electronic components company that deals in integrated optics and photonics components, sub-systems, and optical systems for a range of consumer end-markets, as well as defense and medical sectors.
2. Roma Green Finance Limited (NASDAQ:ROMA)
Year-to-Date Performance: 291.72%
Roma Green Finance Limited (NASDAQ:ROMA) is one of the tiny stocks that are on fire right now. On March 30, Roma Green Finance announced that its board of directors authorized a $100 million share repurchase program, effective immediately. The program, which is set to run through December 31, 2028, allows the company to buy back its Class A Ordinary Shares through various methods, including open market purchases, block trades, and privately negotiated transactions.
This move reflects the company’s discretion in managing its capital allocation and potentially addressing market valuation. The repurchases will be funded through the company’s existing cash reserves and cash flow. While the board has authorized the full amount, the company is not obligated to repurchase a specific number of shares; the actual volume and timing will depend on market conditions, stock price, and liquidity priorities.
Roma Green Finance Limited may also implement these buybacks under Rule 10b5-1 or Rule 10b-18 plans to ensure compliance with SEC regulations regarding market manipulation and insider trading. The share repurchase program signals a step in the company’s financial strategy as it continues to support corporate clients in their transition toward sustainable business practices.
Roma Green Finance Limited is a specialist advisory firm providing ESG, sustainability, and climate change solutions across Hong Kong and Singapore. The company offers reporting, environmental audits, and strategic advisory services to help private companies and NGOs.
1. Adlai Nortye (NASDAQ:ANL)
Year-to-Date Performance: 872.91%
Adlai Nortye (NASDAQ:ANL) is one of the tiny stocks that are on fire right now. On April 16, Adlai Nortye entered into a securities purchase agreement for a private placement equity financing/PIPE expected to yield gross proceeds of ~$150 million. The oversubscribed transaction saw significant participation from a broad group of new and existing institutional healthcare investors, including Soleus Capital, Perceptive Advisors, and Cormorant Asset Management.
The company is selling over 11.3 million American Depositary Shares/ADSs for $13.25 per share, matching its closing price on April 15. The capital infusion is earmarked to advance Adlai Nortye’s clinical-stage pipeline, specifically its RAS-targeting therapies and its proprietary next-generation ADC (antibody-drug conjugate) payload platform, RASiCA. These technologies are central to the company’s mission of transforming terminal cancers into manageable chronic conditions.
As part of the agreement, Adlai Nortye committed to filing a registration statement with the SEC to allow for the resale of the ADSs issued in the placement. High-profile firms, including Leerink Partners and Cantor, served as joint placement agents for the deal, underlining the strong market interest in the company’s specialized oncology platform.
Adlai Nortye is a global clinical-stage company developing innovative cancer therapies through R&D centers in the US and China. Its pipeline features RAS-targeting treatments, including the pan-RAS(ON) inhibitor AN9025, and next-gen immunotherapies like the tri-functional fusion protein AN8025 and oral PD-L1 inhibitor AN4005.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
